Recent Updates — PCMC
On October 15, 2026, Public Company Management Corporation filed a Certificate of Designation with the Nevada Secretary of State establishing three new series of preferred stock: Series A Voting Preferred Stock (1,000,000 shares), Series B-1 Convertible Preferred Stock (25,000,000 shares), and Series B-2 Convertible Preferred Stock (10,000,000 shares). The Series A stock carries no dividend or liquidation rights but entitles holders to two votes for every vote cast by common stockholders plus other preferred series, effectively granting approximately two-thirds of the total voting power. This issuance materially dilutes the relative voting influence of existing and future common shareholders. The Series B-1 and B-2 shares carry one vote per share when combined with common stock and convert into common equity at 4-to-1 and 8-to-1 ratios after 18 and 24 months, respectively. All series automatically convert to common stock upon Nasdaq listing approval or any reorganization event. The company operates as a management consulting firm providing corporate governance and strategic advisory services.
Public Company Management Corporation entered into Amendment No. 1 and Waiver to its Share Exchange Agreement with Physicians Capital Management Corporation and Conrad Ivie, M.D. The amendment revises voting and conversion terms for Series A Voting Preferred Stock and Series B-1 and B-2 Convertible Preferred Stock issued in the transaction. It also corrects references to Physicians' capitalization from 10,000 shares to 10,000,000 authorized and outstanding common shares. Additionally, the amendment waives requirements for a Voting Agreement and Lock-Up Agreement, removing related closing conditions. The company operates in the business of acquiring and managing public companies.
On June 30, 2026, Public Company Management Corporation (PCMC) entered into a Share Exchange Agreement to acquire Physicians Capital Management Corporation from its sole shareholder, Conrad Ivie. In exchange for all outstanding shares of Physicians, PCMC will issue 68,566,368 shares of common stock and 24,913,918 shares of preferred stock (comprising Series A, B-1, and B-2), representing approximately 80% of PCMC's fully diluted outstanding shares. Upon closing, expected in Q3 2026, Conrad Ivie will become CEO and the board will be reconstituted to provide him with control. This transaction will cause PCMC to cease being a shell company. The company will pivot its primary business to healthcare real estate development and ownership. PCMC operates as a healthcare real estate investment and development company.